Cyclerion Therapeutics, Inc. (CYCN)
NASDAQ: CYCN · Real-Time Price · USD
1.680
-0.020 (-1.18%)
At close: Dec 5, 2025, 4:00 PM EST
1.690
+0.010 (0.60%)
After-hours: Dec 5, 2025, 7:56 PM EST
Cyclerion Therapeutics Revenue
Cyclerion Therapeutics had revenue of $875.00K in the quarter ending September 30, 2025, with 351.03% growth. This brings the company's revenue in the last twelve months to $2.86M, up 1,371.65% year-over-year. In the year 2024, Cyclerion Therapeutics had annual revenue of $2.00M.
Revenue (ttm)
$2.86M
Revenue Growth
+1,371.65%
P/S Ratio
1.69
Revenue / Employee
$2,855,000
Employees
1
Market Cap
6.39M
Revenue Chart
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 435.16B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 64.24B |
| AbbVie | 59.64B |
| Eli Lilly and Company | 59.42B |
| AstraZeneca | 58.13B |
| Novartis AG | 56.37B |
| Novo Nordisk | 49.58B |
CYCN News
- 2 months ago - Cyclerion Therapeutics, Inc. - Pre Recorded Special Call - Seeking Alpha
- 2 months ago - Cyclerion Announces Transformational Relaunch as a Neuropsychiatric Company - GlobeNewsWire
- 1 year ago - Cyclerion's sGC Stimulator Portfolio Generates Revenues to Enable Company Growth - GlobeNewsWire
- 1 year ago - Regina Graul, Ph.D., Promoted to Chief Executive Officer - GlobeNewsWire
- 2 years ago - Cyclerion Appoints Regina Graul, Ph.D., as President - GlobeNewsWire
- 2 years ago - Cyclerion Strengthens Board of Directors with Experienced Company Builder and Cutting-edge Innovator - GlobeNewsWire
- 2 years ago - Tisento Launches with $81 Million From Top-Tier Investor Syndicate and Promising Cyclerion Assets - GlobeNewsWire
- 2 years ago - Cyclerion Regains Compliance with Nasdaq Minimum Bid Price Requirement - GlobeNewsWire